Head-To-Head Survey: Tiziana Life Sciences (NASDAQ:TLSA) & CNS Pharmaceuticals (NASDAQ:CNSP)

CNS Pharmaceuticals (NASDAQ:CNSP) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Insider and Institutional Ownership

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

CNS Pharmaceuticals has a beta of 3.06, meaning that its share price is 206% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Valuation & Earnings

This table compares CNS Pharmaceuticals and Tiziana Life Sciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85 million	($29.63)	-0.18
Tiziana Life Sciences	N/A	N/A	-$18.43 million	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for CNS Pharmaceuticals and Tiziana Life Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1	0	1	0	2.00
Tiziana Life Sciences	1	1	0	0	1.50

CNS Pharmaceuticals currently has a consensus price target of $20.00, suggesting a potential upside of 278.79%. Given CNS Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than Tiziana Life Sciences.

Profitability

This table compares CNS Pharmaceuticals and Tiziana Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Tiziana Life Sciences	N/A	N/A	N/A

Summary

CNS Pharmaceuticals beats Tiziana Life Sciences on 6 of the 9 factors compared between the two stocks.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.